Four IPOs and a SPAC pitch a new slate of mi­cro­bio­me, can­cer and in­flam­ma­to­ry drugs to Wall Street

Biotech IPOs are still com­ing in all sorts of fla­vors these days.

Just look at what’s on the menu from Fri­day: There’s Finch Ther­a­peu­tics, which needs the mon­ey to com­plete a sec­ond piv­otal tri­al and start plot­ting com­mer­cial­iza­tion of its mi­cro­bio­me-based prod­ucts; Con­nect Bio­phar­ma, a Chi­nese out­fit go­ing through mid-stage stud­ies in T cell-dri­ven in­flam­ma­to­ry dis­eases; In­stil Bio, whose team is try­ing to ride a com­pas­sion­ate use pro­gram with their au­tol­o­gous tu­mor in­fil­trat­ing lym­pho­cytes straight in­to Phase II; Transcode Ther­a­peu­tics, an un­der-the-radar can­cer ther­a­py de­vel­op­er lever­ag­ing mul­ti­ple RNA modal­i­ties; and then there’s a SPAC — Fore­site Cap­i­tal’s third.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.